JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus maintains an Overweight rating on NeuroPace (NASDAQ:NPCE) and raises the price target from $6 to $9.
November 07, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on NeuroPace and raises the price target from $6 to $9, indicating a positive outlook for the company.
The raised price target by JP Morgan indicates a positive outlook for NeuroPace. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100